GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Inventories, Raw Materials & Components

HLS Therapeutics (TSX:HLS) Inventories, Raw Materials & Components : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Inventories, Raw Materials & Components?

HLS Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2024 was C$0.00 Mil.


HLS Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for HLS Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Inventories, Raw Materials & Components Chart

HLS Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

HLS Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HLS Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


HLS Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.
Executives
Norma Beauchamp Director
Jr. John Lee Welborn Director
Craig Millian Director, Senior Officer
Brian Thomas Walsh Senior Officer
Polar Asset Management Partners Inc. 10% Security Holder
John Gordon Hanna Director, Senior Officer
Athyrium Opportunities Ii Co-invest 1 Lp 10% Security Holder
Tim Hendrickson Senior Officer
William M. Wells Director, Senior Officer
Gilbert Godin Director, Senior Officer
Gregory David Gubitz Director
Orbimed Advisors Llc 10% Security Holder
Jason Gross Senior Officer
Ryan Christopher Lennox Senior Officer

HLS Therapeutics Headlines

No Headlines